

Accurate Detection of Outliers and Subpopulations With Parametric Pharmacometric Modeling and Simulation

Therapeutic Drug Monitoring

34, 467-476

DOI: [10.1097/ftd.0b013e31825c4ba6](https://doi.org/10.1097/ftd.0b013e31825c4ba6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Population Pharmacokinetics of Extended-Infusion Piperacillin-Tazobactam in Hospitalized Patients with Nosocomial Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4087-4094.	1.4	76
2	Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 189-199.	0.8	75
3	Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation. <i>Transplant International</i> , 2013, 26, 1198-1207.	0.8	60
4	Impact of Bolus Dosing versus Continuous Infusion of Piperacillin and Tazobactam on the Development of Antimicrobial Resistance in <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5811-5819.	1.4	72
5	Pharmacokinetics and Pharmacodynamics of Once-Daily Administration of Intravenous Tobramycin in Adult Patients with Cystic Fibrosis Hospitalized for an Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5175-5177.	1.4	11
6	Effects of Obesity and Sex on Antimicrobial Pharmacokinetics and Acute Kidney Injury: Validation of a Preclinical Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 716-722.	1.4	3
7	Pharmacodynamic Target Attainment for Various Ceftazidime Dosing Schemes in High-Flux Hemodialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5854-5859.	1.4	25
8	Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). <i>Infectious Diseases and Therapy</i> , 2014, 3, 269-279.	1.8	16
9	Optimization of Mycophenolic Acid Therapy Using Clinical Pharmacometrics. <i>Drug Metabolism and Pharmacokinetics</i> , 2014, 29, 4-11.	1.1	22
10	Population pharmacokinetics of a single intramuscular administration of tulathromycin in adult desert tortoises (<i>Gopherus agassizii</i>). <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2014, 37, 500-507.	0.6	11
11	Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 836-846.	1.1	16
12	A Population Pharmacokinetic Modeling Approach Shows that Serum Penicillin G Concentrations Are Below Inhibitory Concentrations by Two Weeks after Benzathine Penicillin G Injection in the Majority of Young Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6735-6741.	1.4	13
13	Population Pharmacokinetic–Pharmacodynamic (PK/PD) Modeling of Anti-infective Agents and Its Applications to Individualized Therapy. , 2014, , 113-134.		0
14	Impact of Loading Doses on the Time to Adequate Predicted Beta-Lactam Concentrations in Prolonged and Continuous Infusion Dosing Schemes. <i>Clinical Infectious Diseases</i> , 2014, 59, 905-907.	2.9	28
15	Are Vancomycin Trough Concentrations Adequate for Optimal Dosing?. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 309-316.	1.4	314
16	Population Pharmacokinetics of Teicoplanin in Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6920-6927.	1.4	29
17	Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4094-4102.	1.4	72
18	Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 438-448.	2.3	43

#	ARTICLE	IF	CITATIONS
19	New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients. <i>Pediatric Transplantation</i> , 2014, 18, 103-111.	0.5	44
20	Effect of Protease Inhibitors on Steady-State Pharmacokinetics of Oral Norethindrone Contraception in HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 72-77.	0.9	21
21	Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients—A Prospective, Randomized Study. <i>Transplantation</i> , 2015, 99, 2158-2166.	0.5	77
23	Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? <i>Pseudomonas aeruginosa</i> bloodstream infection in elderly patients as a simulation case study. <i>Fundamental and Clinical Pharmacology</i> , 2015, 29, 615-624.	1.0	5
24	Optimal timing of oral fosfomycin administration for pre-prostate biopsy prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2068-2073.	1.3	33
25	Optimal Methodology Is Important for Optimal Pharmacokinetic Studies, <i>Therapeutic Drug Monitoring and Patient Care. Clinical Pharmacokinetics</i> , 2015, 54, 887-892.	1.6	4
26	Achieving Target Voriconazole Concentrations More Accurately in Children and Adolescents. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3090-3097.	1.4	56
27	Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 798-808.	1.0	3
28	Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 161-167.	1.1	9
29	Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1495-1502.	1.3	60
30	Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2735-2745.	1.4	26
31	Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients. <i>Pharmacological Research</i> , 2015, 99, 308-315.	3.1	22
32	Population Modeling and Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Isoniazid in Lungs. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5181-5189.	1.4	19
33	Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5602-5610.	1.4	87
34	Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2064-2067.	1.3	20
35	Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2854-2861.	1.3	64
36	Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy. <i>MBio</i> , 2015, 6, e01741-15.	1.8	60
37	An Optimized Mouse Thigh Infection Model for Enterococci and Its Impact on Antimicrobial Pharmacodynamics. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 233-238.	1.4	9

#	ARTICLE	IF	CITATIONS
38	Combination Treatment With Meropenem Plus Levofloxacin Is Synergistic Against <i>Pseudomonas aeruginosa</i> Infection in a Murine Model of Pneumonia. <i>Journal of Infectious Diseases</i> , 2015, 211, 1326-1333.	1.9	33
39	Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia. <i>Pediatric Blood and Cancer</i> , 2015, 62, 477-482.	0.8	22
40	Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 332-342.	1.0	53
41	Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?. <i>BMC Pediatrics</i> , 2016, 16, 206.	0.7	31
42	A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 593-599.	1.0	26
43	Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4577-4584.	1.4	38
44	Pharmacokinetics of Vancomycin in Elderly Patients Aged over 80 Years. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4563-4567.	1.4	10
46	Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1885-1891.	1.3	29
47	Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 831-838.	0.8	2
48	Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2336-2342.	1.4	29
49	Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2234-2240.	1.3	10
50	Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5914-5921.	1.4	24
51	Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6550-6557.	1.4	38
52	Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 542-546.	1.1	30
53	High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7333-7339.	1.4	26
54	Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7340-7346.	1.4	35
55	Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoietic Cell Transplantation. <i>Pharmacotherapy</i> , 2016, 36, 1003-1010.	1.2	13
56	Oral Communication Abstracts. <i>Fundamental and Clinical Pharmacology</i> , 2016, 30, 5-24.	1.0	2

#	ARTICLE	IF	CITATIONS
57	Pharmacokinetics of centaquin citrate in a rat model. <i>Journal of Pharmacy and Pharmacology</i> , 2016, 68, 56-62.	1.2	7
58	Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3168-3178.	1.3	21
59	Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6578-6584.	1.4	35
60	Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. <i>Critical Care</i> , 2016, 20, 343.	2.5	47
61	Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5742-5751.	1.4	61
62	Pharmacokinetics of Piperacillin in Critically Ill Australian Indigenous Patients with Severe Sepsis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7402-7406.	1.4	14
63	Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis. <i>Scientific Reports</i> , 2016, 6, 23458.	1.6	35
64	Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4568-4576.	1.4	54
65	Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4901-4909.	1.4	29
66	Pharmacokinetics of centaquin citrate in a dog model. <i>Journal of Pharmacy and Pharmacology</i> , 2016, 68, 803-809.	1.2	6
67	Population Pharmacokinetics of Fixed Dose Combination of Ceftriaxone and Sulbactam in Healthy and Infected Subjects. <i>AAPS PharmSciTech</i> , 2016, 17, 1192-1203.	1.5	13
68	Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 124-131.	1.1	82
69	Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1401-1410.	1.4	51
70	Does Critical Illness Change Levofloxacin Pharmacokinetics?. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1459-1463.	1.4	17
71	Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 992-1002.	1.3	37
72	An exploratory analysis of the ability of a cefepime trough concentration greater than 22Âµg/L to predict neurotoxicity. <i>Journal of Infection and Chemotherapy</i> , 2016, 22, 78-83.	0.8	31
73	Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 484-489.	1.3	25
74	Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1643-1650.	1.3	16

#	ARTICLE	IF	CITATIONS
75	Pharmacodynamics of Isavuconazole in a Dynamic <i>In Vitro</i> Model of Invasive Pulmonary Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 278-287.	1.4	23
76	Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 464-470.	1.3	36
77	Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 189-195.	1.3	25
78	Effect of <i>Lactobacillus casei</i> on the Pharmacokinetics of Amiodarone in Male Wistar Rats. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2017, 42, 29-36.	0.6	13
79	Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	54
80	Population Pharmacokinetics and Pharmacodynamic Target Attainment of Ampicillin in Neonates with Hypoxic-Ischemic Encephalopathy in the Setting of Controlled Hypothermia. <i>Pharmacotherapy</i> , 2017, 37, 456-463.	1.2	15
81	Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with hematological malignancy. <i>Clinical Microbiology and Infection</i> , 2017, 23, 674.e7-674.e13.	2.8	29
82	Is continuous infusion of imipenem always the best choice?. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 348-354.	1.1	7
83	Population Pharmacokinetics and Bayesian Estimators for Refined Dose Adjustment of a New Tacrolimus Formulation in Kidney and Liver Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1491-1498.	1.6	39
84	Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	27
85	Short-Course, High-Dose Rifampicin Achieves <i>Wolbachia</i> Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis. <i>Scientific Reports</i> , 2017, 7, 210.	1.6	65
86	Pilot Study of a Bayesian Approach To Estimate Vancomycin Exposure in Obese Patients with Limited Pharmacokinetic Sampling. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	24
87	Limited sampling strategies for determining the area under the plasma concentration-time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 23-28.	1.1	12
88	Fexofenadine, a Putative <i>In Vivo</i> Glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 989-996.	2.3	10
89	Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. <i>Clinical Infectious Diseases</i> , 2017, 64, 1557-1563.	2.9	39
90	A Time-Dependent Model Describes Methotrexate Elimination and Supports Dynamic Modification of MRP2/ABCC2 Activity. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 145-156.	1.0	12
91	Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1433-1440.	1.3	20
93	Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: a randomized controlled trial. <i>British Journal of Anaesthesia</i> , 2017, 118, 876-882.	1.5	25

#	ARTICLE	IF	CITATIONS
94	A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. <i>Nature Communications</i> , 2017, 8, 15159.	5.8	51
95	Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	52
96	Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of <i>Mycobacterium tuberculosis</i> . <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3703-3726.	2.9	39
97	Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 712-719.	1.0	22
98	Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	24
99	Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1057-1068.	1.6	32
100	Vancomycin therapy in secondary care; investigating factors that impact therapeutic target attainment. <i>Journal of Infection</i> , 2017, 74, 320-324.	1.7	1
101	Evaluating Clinical Effectiveness and Pharmacokinetic Profile of Atomized Intranasal Midazolam in Children Undergoing Laceration Repair. <i>Journal of Emergency Medicine</i> , 2017, 53, 397-404.	0.3	12
102	Pharmacodynamics of teicoplanin against MRSA. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3382-3389.	1.3	40
104	Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	44
105	24-Hour Pharmacokinetic Relationships for Vancomycin and Novel Urinary Biomarkers of Acute Kidney Injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	39
106	Tools for the Individualized Therapy of Teicoplanin for Neonates and Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	14
107	Albendazole and antibiotics synergize to deliver short-course anti- <i>Wolbachia</i> curative treatments in preclinical models of filariasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E9712-E9721.	3.3	47
108	Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 482-486.	1.1	21
109	Evaluation of haemodialysis as a protective technique for preventing high daily dose amikacin nephrotoxicity: an experimental study in an ovine model. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 148-154.	1.1	3
110	Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support. <i>Pediatric Critical Care Medicine</i> , 2017, 18, 977-985.	0.2	24
111	A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics. <i>Clinical Pharmacokinetics</i> , 2017, 56, 435-447.	1.6	11
112	Controlling Busulfan Therapy in Children. , 2017, , 307-326.		0

#	ARTICLE	IF	CITATIONS
113	Describing Drug Behavior in Groups of Patients. , 2017, , 19-25.		0
114	Controlling Antiretroviral Therapy in Children and Adolescents with HIV Infection. , 2017, , 207-238.		0
115	The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma. <i>Cancer Management and Research</i> , 2017, Volume 9, 731-739.	0.9	9
116	Prophylactic cefazolin concentrations in morbidly obese patients undergoing sleeve gastrectomy: do we achieve targets?. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 28-34.	1.1	12
117	Exploring the Use of C-Reactive Protein to Estimate the Pharmacodynamics of Vancomycin. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 315-321.	1.0	11
118	Population pharmacokinetics and pharmacodynamics of fosfomycin in non-“critically ill patients with bacteremic urinary infection caused by multidrug-resistant <i>Escherichia coli</i> . <i>Clinical Microbiology and Infection</i> , 2018, 24, 1177-1183.	2.8	18
119	Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	5
120	Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose. <i>Pharmacological Research</i> , 2018, 130, 316-321.	3.1	34
121	Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1340-1347.	1.3	30
122	Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by <i>Aspergillus flavus</i> . <i>Journal of Infectious Diseases</i> , 2018, 217, 1118-1127.	1.9	47
123	Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 594-600.	1.1	38
124	Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	8
125	Interchangeability of Generic Drugs: A Nonparametric Pharmacokinetic Model of Gabapentin Generic Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 966-973.	2.3	6
126	Population Pharmacokinetics of Polymyxin B in Acutely Ill Adult Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	65
127	Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 995-1003.	1.3	34
128	Higher than standard meropenem and linezolid dosages needed for appropriate treatment of an intracerebral hemorrhage patient with augmented renal clearance. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1091-1092.	0.8	5
129	Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	38
130	A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1459-1469.	1.6	12

#	ARTICLE	IF	CITATIONS
131	Population pharmacokinetics and probability of target attainment of ertapenem administered by subcutaneous or intravenous route in patients with bone and joint infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 987-994.	1.3	19
132	Morphine Pharmacokinetics in Children With Down Syndrome Following Cardiac Surgery. <i>Pediatric Critical Care Medicine</i> , 2018, 19, 459-467.	0.2	5
133	Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1399-1405.	1.6	13
134	Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 151-157.	1.1	25
135	Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV+ Population Is Not Related to Antiretroviral Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 449-457.	2.3	13
136	Maximally effective dosing regimens of meropenem in patients with septic shock. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 191-198.	1.3	40
137	Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients. <i>Clinical Pharmacokinetics</i> , 2018, 57, 989-1000.	1.6	26
138	Population Pharmacokinetics of Gentamicin in Neonates with Hypoxemic Ischemic Encephalopathy Receiving Controlled Hypothermia. <i>Pharmacotherapy</i> , 2018, 38, 1120-1129.	1.2	6
139	The Combination of Fosfomycin plus Meropenem Is Synergistic for <i>Pseudomonas aeruginosa</i> PAO1 in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	33
140	Continuous infusion versus intermittent bolus doses of fentanyl for analgesia and sedation in neonates: an open-label randomised controlled trial. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2019, 104, fetalneonatal-2018-315345.	1.4	13
141	Dosing vancomycin in the super obese: less is more. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3081-3086.	1.3	40
142	Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1671-1672.	0.8	7
143	Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients. <i>Pharmacotherapy</i> , 2018, 38, 730-738.	1.2	36
144	Exposure-Response Analysis of Micafungin in Neonatal Candidiasis. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 580-585.	1.1	5
145	Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2996-3005.	1.4	11
146	Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	12
147	Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with <i>Candida albicans</i> and non- <i>albicans</i> spp.. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1449-1459.	0.8	6
148	Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives. <i>Pharmacological Research</i> , 2018, 134, 280-288.	3.1	94

#	ARTICLE	IF	CITATIONS
149	Î²-Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	49
150	Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study. <i>Critical Care</i> , 2018, 22, 25.	2.5	28
151	Population pharmacokinetics/pharmacodynamics of micafungin against <i>Candida</i> species in obese, critically ill, and morbidly obese critically ill patients. <i>Critical Care</i> , 2018, 22, 94.	2.5	43
152	Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis. <i>Annals of Pharmacotherapy</i> , 2018, 52, 965-973.	0.9	14
153	Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	5
154	Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	9
155	Optimizing Gentamicin Dosing in Pediatrics Using Monte Carlo Simulations. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 390-395.	1.1	9
156	Pharmacokineticsâ€Pharmacodynamics of Highâ€Dose Ivermectin with Dihydroartemisininâ€Piperazine on Mosquitocidal Activity and <scp>QT</scp>â€Prolongation (<scp>IVERMAL</scp>). <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 388-401.	2.3	28
157	Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children. <i>Bone Marrow Transplantation</i> , 2019, 54, 448-457.	1.3	31
158	Population Pharmacokinetic Study of Cefazolin Dosage Adaptation in Bacteremia and Infective Endocarditis Based on a Nomogram. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	13
160	Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1405-1414.	0.8	9
161	Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007). <i>Infectious Diseases and Therapy</i> , 2019, 8, 383-396.	1.8	14
162	The lower limit of quantification in pharmacokinetic analyses. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2019, 42, 585-587.	0.6	10
163	Death with an implantable cardioverter-defibrillator: a MADIT-II substudy. <i>Europace</i> , 2019, 21, 1843-1850.	0.7	5
165	Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1012-1020.	1.3	12
166	Augmented renal clearance of aminoglycosides using population-based pharmacokinetic modelling with Bayesian estimation in the paediatric ICU. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 162-169.	1.3	9
167	Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize <i>A Priori</i> Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	16
168	In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for <i>Neisseria gonorrhoeae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3521-3529.	1.3	24

#	ARTICLE	IF	CITATIONS
170	Microneedle biosensors for real-time, minimally invasive drug monitoring of phenoxymethylpenicillin: a first-in-human evaluation in healthy volunteers. <i>The Lancet Digital Health</i> , 2019, 1, e335-e343.	5.9	96
171	Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine. <i>Malaria Journal</i> , 2019, 18, 325.	0.8	46
172	Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 741-749.	1.1	14
174	A pharmacokinetic model for voriconazole in a highly diversified population of children and adolescents with cancer. <i>Mycoses</i> , 2019, 62, 399-404.	1.8	7
175	Pharmacokinetics of cefazolin delivery via the cardiopulmonary bypass circuit priming solution in infants and children. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1342-1347.	1.3	9
176	CSF penetration of vancomycin in critical care patients with proven or suspected ventriculitis: a prospective observational study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 991-996.	1.3	19
177	Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	16
178	Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	10
179	Intracellular PD Modelling (PDi) for the Prediction of Clinical Activity of Increased Rifampicin Dosing. <i>Pharmaceutics</i> , 2019, 11, 278.	2.0	4
180	Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2676-2680.	1.3	4
181	High-Dose Ceftriaxone for Bacterial Meningitis and Optimization of Administration Scheme Based on Nomogram. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	21
182	Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1219-1226.	0.8	17
183	Repurposing azithromycin for neonatal neuroprotection. <i>Pediatric Research</i> , 2019, 86, 444-451.	1.1	27
184	Population Pharmacokinetics of Anidulafungin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	12
185	Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2326-2334.	1.3	41
186	Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	13
187	Population pharmacokinetic model and Bayesian estimator for 2 tacrolimus formulations in adult liver transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1740-1750.	1.1	16
188	Population pharmacokinetics of continuous-infusion ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1648-1655.	1.3	11

#	ARTICLE	IF	CITATIONS
189	Gut microbiota metabolizes nabumetone <i>in vitro</i> : Consequences for its bioavailability <i>in vivo</i> in the rodents with altered gut microbiome. <i>Xenobiotica</i> , 2019, 49, 1296-1302.	0.5	13
190	Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin. <i>PLoS ONE</i> , 2019, 14, e0211096.	1.1	3
191	A Translational Pharmacokinetic Rat Model of Cerebral Spinal Fluid and Plasma Concentrations of Cefepime. <i>MSphere</i> , 2019, 4, .	1.3	4
192	Defining optimal dosing of ciprofloxacin in patients with septic shock. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1662-1669.	1.3	18
193	Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	1.4	5
194	Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. <i>MBio</i> , 2019, 10, .	1.8	44
195	Pharmacokinetics of Micafungin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis With High Cutoff Membranes. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 376-382.	1.0	4
196	Nonparametric Population Pharmacokinetic Modeling of Isoniazid in Colombian Patients With Tuberculosis. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 719-725.	1.0	4
197	Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated <i>Salmonella Typhi</i> infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007955.	1.3	21
198	A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 11-18.	1.0	11
199	Lung Pharmacokinetics of Tobramycin by Intravenous and Nebulized Dosing in a Mechanically Ventilated Healthy Ovine Model. <i>Anesthesiology</i> , 2019, 131, 344-355.	1.3	17
200	Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 432-441.	1.3	43
201	Population Pharmacodynamics of Amphotericin B Deoxycholate for Disseminated Infection Caused by <i>Talaromyces marneffei</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	6
202	Pharmacokinetics of a novel, approved, 1.4-µg intranasal naloxone formulation for reversal of opioid overdose—a randomized controlled trial. <i>Addiction</i> , 2019, 114, 859-867.	1.7	15
203	Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 529-542.	0.8	7
204	AWZ1066S, a highly specific anti- <i>Wolbachia</i> drug candidate for a short-course treatment of filariasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1414-1419.	3.3	57
205	An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Journal of Clinical Pharmacology</i> , 2019, 59, 198-205.	1.0	15
206	Is One Sample Enough? ¹² -Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	5

#	ARTICLE	IF	CITATIONS
207	Plasma and interstitial fluid population pharmacokinetics of vancomycin in critically ill patients with sepsis. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 137-142.	1.1	14
208	Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help?. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 126-129.	1.3	2
209	Toxicity induced by multiple high doses of vitamin B ₁₂ during pernicious anemia treatment: a case report. <i>Clinical Toxicology</i> , 2020, 58, 129-131.	0.8	17
210	Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis. <i>Clinical Pharmacokinetics</i> , 2020, 59, 327-334.	1.6	13
211	Expert Discussion of the Role of Rate Constant Versus Clearance Approaches to Define Drug Pharmacokinetics: Theoretical and Clinical Considerations. <i>AAPS Journal</i> , 2020, 22, 25.	2.2	0
212	Pharmacokinetic methods for TDM data analysis and optimal individualization of drug dosage regimens. <i>Handbook of Analytical Separations</i> , 2020, 7, 135-168.	0.8	3
213	Measured GFR by Utilizing Population Pharmacokinetic Methods to Determine Iohexol Clearance. <i>Kidney International Reports</i> , 2020, 5, 189-198.	0.4	13
214	Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 407-414.	1.0	20
215	Efficacy of Telavancin in Comparison to Linezolid in a Porcine Model of Severe Methicillin-Resistant <i>Staphylococcus aureus</i> Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	1
216	Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	10
217	Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against <i>Pseudomonas aeruginosa</i> in a Dynamic <i>In Vitro</i> Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	7
218	Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	15
219	A Population Pharmacokinetic Analysis of Continuous Infusion of Cloxacillin during <i>Staphylococcus aureus</i> Bone and Joint Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	8
220	Prolonged Versus Intermittent Infusion of β -Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1237-1250.	1.6	18
221	Fasting Status and Circadian Variation Must be Considered When Performing AUC ₀₋₂₄ -based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients. <i>Clinical and Translational Science</i> , 2020, 13, 1327-1335.	1.5	9
222	Population Pharmacokinetics of Cefoxitin Administered for Pediatric Cardiac Surgery Prophylaxis. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 609-614.	1.1	2
223	Pharmacodynamics of the Novel Metallo- β -Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing <i>Enterobacteriaceae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	11
224	Nonparametric Methods in Population Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 142-157.	1.0	28

#	ARTICLE	IF	CITATIONS
225	Baclofen self-poisoning: Is renal replacement therapy efficient in patient with normal kidney function?. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 813-817.	0.6	2
226	Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and <i>P. aeruginosa</i> . <i>Pharmaceutics</i> , 2020, 12, 785.	2.0	6
227	Building Optimal Three-Drug Combination Chemotherapy Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	11
228	Population pharmacokinetics of gentamicin in haemodialysis patients: modelling, simulations and recommendations. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 947-955.	0.8	3
229	Evaluation of Dose-Fractionated Polymyxin B on Acute Kidney Injury Using a Translational <i>In Vivo</i> Rat Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	5
230	Pharmacokinetic Assessment of Pre- and Post-Oxygenator Vancomycin Concentrations in Extracorporeal Membrane Oxygenation: A Prospective Observational Study. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1575-1587.	1.6	6
231	Dose optimization of early high-dose valproic acid for neuroprotection in a swine cardiac arrest model. <i>Resuscitation Plus</i> , 2020, 1-2, 100007.	0.6	1
232	Pharmacokinetics and Pharmacodynamics of Linezolid in Patients With Sepsis Receiving Continuous Venovenous Hemofiltration and Extended Daily Hemofiltration. <i>Journal of Infectious Diseases</i> , 2020, 221, S279-S287.	1.9	6
233	Intra-individual Pharmacokinetic Variability of Intravenous Busulfan in Hematopoietic Stem Cell-Transplanted Children. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1049-1061.	1.6	18
234	Development of a methodology to make individual estimates of the precision of liquid chromatography-tandem mass spectrometry drug assay results for use in population pharmacokinetic modeling and the optimization of dosage regimens. <i>PLoS ONE</i> , 2020, 15, e0229873.	1.1	8
235	Pharmacogeneticâ€”Whole blood and intracellular pharmacokineticâ€”Pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients. <i>PLoS ONE</i> , 2020, 15, e0230195.	1.1	24
236	Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1027-1036.	1.6	11
237	Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	25
238	Development and validation of a dosing nomogram for amoxicillin in infective endocarditis. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2941-2950.	1.3	7
239	Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with <i>Schistosoma japonicum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	5
240	Ethionamide Population Pharmacokinetic Model and Target Attainment in Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	6
241	Comparison of Body Size, Morphometrics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma. <i>Pharmacotherapy</i> , 2020, 40, 308-319.	1.2	12
242	Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. <i>Critical Care</i> , 2020, 24, 55.	2.5	34

#	ARTICLE	IF	CITATIONS
243	Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1550-1559.	1.1	9
244	Disposition of Oral Cannabidiol-Rich Cannabis Extracts in Children with Epilepsy. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1005-1012.	1.6	6
245	Pharmacokinetics of TKM-130803 in Sierra Leonean patients with Ebola virus disease: Plasma concentrations exceed target levels, with drug accumulation in the most severe patients. <i>EBioMedicine</i> , 2020, 52, 102601.	2.7	7
246	Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate. <i>Clinical Pharmacokinetics</i> , 2020, 59, 885-898.	1.6	9
247	Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum- β -Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	15
248	Ceftriaxone dosing in patients admitted from the emergency department with sepsis. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 207-214.	0.8	3
249	Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	1
250	Roger W. Jelliffe, MD, FCP, FAAPS. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 22-24.	2.3	0
251	Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	6
252	The Pharmacodynamic-Toxicodynamic Relationship of AUC and C_{max} in Vancomycin-Induced Kidney Injury in an Animal Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	13
253	Effect of Body Fat on Population Pharmacokinetics of High-Dose Methotrexate in Pediatric Patients With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 755-762.	1.0	7
254	Pharmacodynamic Analysis of Meropenem and Fosfomycin Combination Against Carbapenem-Resistant <i>Acinetobacter baumannii</i> in Patients with Normal Renal Clearance: Can It Be a Treatment Option?. <i>Microbial Drug Resistance</i> , 2021, 27, 546-552.	0.9	5
255	Ebola virus antibody decay stimulation in a high proportion of survivors. <i>Nature</i> , 2021, 590, 468-472.	13.7	30
256	Increasing adoption rates at animal shelters: a two-phase approach to predict length of stay and optimal shelter allocation. <i>BMC Veterinary Research</i> , 2021, 17, 70.	0.7	18
257	A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 747-755.	1.0	3
258	Population pharmacokinetics of daptomycin in patients with bone and joint infection: minimal effect of rifampicin co-administration and confirmation of a sex difference. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1250-1257.	1.3	9
259	Ampicillin Pharmacokinetics During First Week of Life in Preterm and Term Neonates. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 464-472.	1.1	4
260	Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	15

#	ARTICLE	IF	CITATIONS
261	Population Pharmacokinetic Models of Antituberculosis Drugs in Patients: A Systematic Critical Review. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 108-115.	1.0	7
262	Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae. <i>Antibiotics</i> , 2021, 10, 348.	1.5	3
263	Population pharmacokinetic model of isoniazid in patients with tuberculosis in Tunisia. <i>International Journal of Infectious Diseases</i> , 2021, 104, 562-567.	1.5	4
264	Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	4
265	Optimizing Aminoglycoside Dosing Regimens for Critically Ill Pediatric Patients with Augmented Renal Clearance: a Convergence of Parametric and Nonparametric Population Approaches. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	6
266	Maraviroc exposure is influenced by exogenous thyrotoxicosis. <i>Aids</i> , 2021, 35, 701-703.	1.0	0
267	Development of a population pharmacokinetic model and Bayesian estimators for isoniazid in Tunisian tuberculosis patients. <i>Pharmacogenomics Journal</i> , 2021, 21, 467-475.	0.9	3
268	Population Pharmacokinetics and Monte Carlo Simulation for Dosage Optimization of Fosfomycin in the Treatment of Osteoarticular Infections in Patients without Renal Dysfunction. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	7
269	Effectiveness of Pharmacokinetic/Pharmacodynamic-Guided Meropenem Treatment in Critically Ill Patients: A Comparative Cohort Study. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 256-263.	1.0	7
270	Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of <i>Acinetobacter baumannii</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1943-1952.	1.3	6
272	Clinical application of intrathecal gadobutrol for assessment of cerebrospinal fluid tracer clearance to blood. <i>JCI Insight</i> , 2021, 6, .	2.3	30
273	Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against <i>Pseudomonas aeruginosa</i> . <i>Drugs in R and D</i> , 2021, 21, 203-215.	1.1	2
274	Semimechanistic Pharmacokinetic/Pharmacodynamic Modeling of Fosfomycin and Sulbactam Combination against Carbapenem-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	8
275	Pharmacokinetic Disposition of Amiodarone When Given with an Intralipid Rescue Strategy. <i>Pharmaceutics</i> , 2021, 13, 539.	2.0	0
276	Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	7
277	Emergence of Resistance to Ceftazidime-Avibactam in a <i>Pseudomonas aeruginosa</i> Isolate Producing Derepressed <i>bla_{CTX-M}</i> in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	8
278	Dosage Individualization of Linezolid: Precision Dosing of Linezolid To Optimize Efficacy and Minimize Toxicity. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	12
279	Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against <i>Neisseria gonorrhoeae</i> in a Dynamic Hollow Fiber Infection Model. <i>Frontiers in Pharmacology</i> , 2021, 12, 682135.	1.6	23

#	ARTICLE	IF	CITATIONS
280	Prospective Cohort Study of Micafungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-abdominal Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0230720.	1.4	4
281	Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0029321.	1.4	12
282	Population Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0143821.	1.4	9
283	Pharmacokinetics of levetiracetam in neurosurgical ICU patients. <i>Journal of Critical Care</i> , 2021, 64, 255-261.	1.0	12
284	Short- and long-term effects of body weight loss following calorie restriction and gastric bypass on CYP3A activity: a non-randomized three-armed controlled trial. <i>Clinical and Translational Science</i> , 2022, 15, 221-233.	1.5	13
285	Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by <i>Talaromyces marneffei</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0063621.	1.4	5
286	Pharmacokinetic/Pharmacodynamic Dosage Individualization of Cefepime in Critically Ill Patients: A Case Study. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 451-454.	1.0	2
287	A Population Pharmacokinetic Modeling Approach to Determine the Efficacy of Intravenous Amikacin in Children with Cystic Fibrosis. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 499-504.	1.0	1
288	Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0073721.	1.4	5
289	Building Optimal Three-Drug Combination Chemotherapy Regimens To Eradicate <i>Mycobacterium tuberculosis</i> in Its Slow-Growth Acid Phase. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0069321.	1.4	4
290	A pharmacokinetics-based approach to the monitoring of patient adherence to atorvastatin therapy. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00856.	1.1	2
291	Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against <i>Enterobacteriales</i> and <i>Pseudomonas aeruginosa</i> . <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106408.	1.1	12
292	Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients. <i>Antibiotics</i> , 2021, 10, 100.	1.5	2
293	Endpoint Assessment in Rabbit Models of Invasive Pulmonary Aspergillosis and Mucormycosis. <i>Methods in Molecular Biology</i> , 2017, 1625, 259-277.	0.4	3
294	Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1025-1031.	1.3	18
295	Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2342-2350.	1.3	26
296	Vancomycin Exposure and Acute Kidney Injury Outcome: A Snapshot From the CAMERA2 Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa538.	0.4	21
297	Cefuroxime pharmacokinetics and pharmacodynamics for intravenous dosage regimens with 750 mg or 1500 mg doses in healthy young volunteers. <i>Journal of Medical Microbiology</i> , 2020, 69, 387-395.	0.7	5

#	ARTICLE	IF	CITATIONS
299	Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	2
300	Pharmacodynamics of the Orotomides against <i>Aspergillus fumigatus</i> : New Opportunities for Treatment of Multidrug-Resistant Fungal Disease. <i>MBio</i> , 2017, 8, .	1.8	47
301	Analysis of Combination Drug Therapy to Develop Regimens with Shortened Duration of Treatment for Tuberculosis. <i>PLoS ONE</i> , 2014, 9, e101311.	1.1	56
302	CYP2B6 Genotype Guided Dosing of Propofol Anesthesia in the Elderly Based on Nonparametric Population Pharmacokinetic Modeling and Simulations. <i>International Journal of Clinical Pharmacology & Toxicology</i> , 0, , 242-249.	1.0	7
303	An Algorithm for Nonparametric Estimation of a Multivariate Mixing Distribution with Applications to Population Pharmacokinetics. <i>Pharmaceutics</i> , 2021, 13, 42.	2.0	12
304	Vancomycin Dosing and Pharmacokinetics in Postoperative Pediatric Cardiothoracic Surgery Patients. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2016, 21, 66-74.	0.3	9
305	Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2017, 22, 276-285.	0.3	44
306	Use of Simulation Strategies to Predict Subtherapeutic Meropenem Exposure Caused by Augmented Renal Clearance in Critically Ill Pediatric Patients With Sepsis. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2020, 25, 413-422.	0.3	11
307	Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 466-473.	1.3	6
308	Population Pharmacokinetics of Vancomycin in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation (an ASAP ECMO Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0137721.	1.4	7
309	Applying Cefepime Population Pharmacokinetics to Critically Ill Patients Receiving Continuous Renal Replacement Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0161121.	1.4	4
310	Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106466.	1.1	12
312	Data characterization. , 2017, , 15-43.		0
315	The New Direct-Acting Oral Anticoagulants Need to be Monitored!. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 357-359.	1.0	0
316	Determination of Pharmacokinetic Parameters of a Four-Armed, Guanidinium-Rich Structurally Nanoengineered Antimicrobial Peptide Polymer: A Research Protocol. , 2020, 4, 1-9.		0
317	Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts' Discussion on Use, Strengths, and Limitations. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 158-170.	1.0	9
318	A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone. <i>PLoS ONE</i> , 2020, 15, e0243365.	1.1	6
319	Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients. <i>Infectious Diseases and Therapy</i> , 2022, 11, 201-216.	1.8	6

#	ARTICLE	IF	CITATIONS
320	CYP2B6 Genotype Guided Dosing of Propofol Anesthesia in the Elderly based on Nonparametric Population Pharmacokinetic Modeling and Simulations. <i>International Journal of Clinical Pharmacology & Toxicology</i> , 2017, 6, 242-249.	1.0	7
321	Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 711-718.	1.3	11
322	Effect of Blood Product Resuscitation on the Pharmacokinetics of Ampicillin-Sulbactam during Orthotopic Liver Transplantation. <i>Surgical Infections</i> , 2021, , .	0.7	0
323	The PHARMACOM&EPI Framework for Integrating Pharmacometric Modelling Into Pharmacoepidemiological Research Using Real-World Data: Application to Assess Death Associated With Valproate. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 840-856.	2.3	4
324	Nonparametric Estimation of Blood Alcohol Concentration from Transdermal Alcohol Measurements Using Alcohol Biosensor Devices. <i>Association for Women in Mathematics Series</i> , 2021, , 329-360.	0.1	2
325	Pharmacokinetic/Pharmacodynamic Simulations of Cost-Effective Dosage Regimens of Cefotolozane-Tazobactam and Ceftazidime-Avibactam in Patients with Renal Impairment. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0210421.	1.4	2
326	Pharmacokinetics of Cefazolin in Patients With Obesity Undergoing Surgery Requiring Cardiopulmonary Bypass. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 2942-2947.	0.6	2
327	Implementation and Comparison of Two Pharmacometric Tools for Model-Based Therapeutic Drug Monitoring and Precision Dosing of Daptomycin. <i>Pharmaceutics</i> , 2022, 14, 114.	2.0	8
328	Pharmacodynamics of ceftriaxone for the treatment of methicillin-resistant Staphylococcus aureus: is it a viable treatment option?. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106537.	1.1	10
329	Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1334-1343.	1.3	8
330	Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0204621.	1.4	9
331	Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0218121.	1.4	1
332	Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study). <i>Clinical Pharmacokinetics</i> , 2022, 61, 847-856.	1.6	8
333	Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol. <i>Pharmacogenomics and Personalized Medicine</i> , 2022, Volume 15, 249-260.	0.4	1
334	Impact of Maximizing C _{ss} /MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization. <i>Frontiers in Pharmacology</i> , 2021, 12, 781892.	1.6	12
335	Parametric and Nonparametric Population Pharmacokinetic Models to Assess Probability of Target Attainment of Imipenem Concentrations in Critically Ill Patients. <i>Pharmaceutics</i> , 2021, 13, 2170.	2.0	2
336	Exploring population pharmacokinetic models in patients treated with vancomycin during continuous venovenous haemodiafiltration (CVVHDF). <i>Critical Care</i> , 2021, 25, 443.	2.5	3
337	Caspofungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-Abdominal Infections: A Prospective Cohort Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 673-686.	1.6	3

#	ARTICLE	IF	CITATIONS
338	Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against <i>Aspergillus fumigatus</i> and <i>Aspergillus flavus</i> in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?. <i>Pharmaceutics</i> , 2021, 13, 2099.	2.0	12
339	Pharmacodynamic Evaluation of Zoliflodacin Treatment of <i>Neisseria gonorrhoeae</i> Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model. <i>Frontiers in Pharmacology</i> , 2022, 13, 874176.	1.6	15
340	Vancomycin Pharmacokinetics in a Pregnancy Rat Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0005622.	1.4	1
342	Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2022, , 101080.	0.6	3
343	Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO). <i>International Journal of Antimicrobial Agents</i> , 2022, 60, 106603.	1.1	7
344	Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0218921.	1.4	8
345	Population pharmacokinetics and dose optimization of intravenous levofloxacin in hospitalized adult patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
346	Correlations between 4 β -hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 1289-1299.	0.8	9
347	Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	12
348	Assessment of Antibiotic Pharmacokinetics, Molecular Biomarkers and Clinical Status in Critically Ill Adults Diagnosed with Community-Acquired Pneumonia and Receiving Intravenous Piperacillin/Tazobactam and Hydrocortisone over the First Five Days of Intensive Care: An Observational Study (STROBE Compliant). <i>Journal of Clinical Medicine</i> , 2022, 11, 4140.	1.0	2
349	Population pharmacokinetic modeling of CSF to blood clearance: prospective tracer study of 161 patients under work-up for CSF disorders. <i>Fluids and Barriers of the CNS</i> , 2022, 19, .	2.4	16
350	Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	4
351	Population Pharmacokinetics of Temocillin Administered by Continuous Infusion in Patients with Septic Shock Associated with Intra-Abdominal Infection and Ascitic Fluid Effusion. <i>Antibiotics</i> , 2022, 11, 898.	1.5	4
352	Impact of Inflammation on Midazolam Metabolism in Severe COVID-19 Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 1033-1039.	2.3	6
353	Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	5
354	Individual target pharmacokinetic/pharmacodynamic attainment rates among meropenem-treated patients admitted to the ICU with hospital-acquired pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2956-2959.	1.3	1
355	A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib. <i>Molecules</i> , 2022, 27, 4766.	1.7	0
356	Model-Informed Rationale for Early Therapeutic Drug Monitoring of Colistin in Critically Ill Patients. <i>Journal of Clinical Pharmacology</i> , 0, , .	1.0	1

#	ARTICLE	IF	CITATIONS
357	Predicting Tacrolimus Exposure in Kidney Transplanted Patients Using Machine Learning. , 2022, , .		2
358	A pharmacometrics model to define docetaxel target in early breast cancer. British Journal of Clinical Pharmacology, 0, , .	1.1	2
359	Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype. Antimicrobial Agents and Chemotherapy, 2022, 66, .	1.4	2
360	Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings. Journal of Antimicrobial Chemotherapy, 2022, 77, 3349-3357.	1.3	2
361	Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome <scp>P450</scp> in patients with obesity. Clinical and Translational Science, 2022, 15, 2685-2696.	1.5	9
362	Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study. Annals of Intensive Care, 2022, 12, .	2.2	6
363	Optimizing Meropenem in Highly Resistant Klebsiella pneumoniae Environments: Population Pharmacokinetics and Dosing Simulations in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2022, 66, .	1.4	3
364	Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis. MBio, 2022, 13, .	1.8	4
365	Closed-loop control of continuous piperacillin delivery: An in silico study. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	0
366	Shedding a Light on Acyclovir Pharmacodynamics: A Retrospective Analysis on Pharmacokinetic/Pharmacodynamic Modelling of Acyclovir for the Treatment of Varicella Zoster Virus Infection in Immunocompromised Patients: A Pilot Study. Pharmaceutics, 2022, 14, 2311.	2.0	1
367	Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhoea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections. Frontiers in Pharmacology, 0, 13, .	1.6	6
368	Individualized Patient Care Through Model-Informed Precision Dosing: Reflections on Training Future Practitioners. AAPS Journal, 2022, 24, .	2.2	2
369	Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis. Journal of Antimicrobial Chemotherapy, 2023, 78, 276-283.	1.3	1
370	A proof of concept reinforcement learning based tool for non parametric population pharmacokinetics workflow optimization. Journal of Pharmacokinetics and Pharmacodynamics, 0, , .	0.8	1
371	Interchangeability of generic drugs for subpopulations: bioequivalence simulation from a non-parametric PK model of gabapentin generic drugs.. British Journal of Clinical Pharmacology, 0, , .	1.1	0
372	Beta-lactam target attainment and associated outcomes in patients with bloodstream infections. International Journal of Antimicrobial Agents, 2023, 61, 106727.	1.1	14
373	Development of a Predictive Dosing Nomogram to Achieve PK/PD Targets of Amikacin Initial Dose in Critically Ill Patients: A Non-Parametric Approach. Antibiotics, 2023, 12, 123.	1.5	1
374	Sorting Out the Risks and Benefits of the #797 Recommended Intrapartum Vancomycin Dosing Approach. Antibiotics, 2023, 12, 32.	1.5	0

#	ARTICLE	IF	CITATIONS
375	Isavuconazole Pharmacokinetics and Pharmacodynamics in Children. <i>Pharmaceutics</i> , 2023, 15, 75.	2.0	0
376	Pharmacokinetic/Pharmacodynamic Index Linked to <i>In Vivo</i> Efficacy of the Ampicillin-Ceftriaxone Combination against <i>Enterococcus faecalis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2023, 67, .	1.4	1
377	Population Pharmacokinetics of Vancomycin in Patients Receiving Hemodialysis in a Malian and a French Center and Simulation of the Optimal Loading Dose. <i>Therapeutic Drug Monitoring</i> , 2023, 45, 637-643.	1.0	3
378	Impact of Fasting Status and Circadian Variation on the Pharmacokinetics of Mycophenolate Mofetil and the Glucuronide Metabolite in Renal Transplant Recipients. <i>Transplantation Direct</i> , 2023, 9, e1448.	0.8	0
379	Development and validation of a dosing nomogram for continuous infusion cloxacillin in infective endocarditis. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 965-974.	1.3	0
380	Population Pharmacokinetic and Pharmacodynamic Analysis of Valganciclovir for Optimizing Preemptive Therapy of Cytomegalovirus Infections in Kidney Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	1.4	2
381	Population Pharmacokinetics of Ganciclovir in Allogeneic Hematopoietic Stem Cell Transplant Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	1.4	1
382	Population Pharmacokinetics and Dosing Simulations of Ampicillin and Sulbactam in Hospitalised Adult Patients. <i>Clinical Pharmacokinetics</i> , 2023, 62, 573-586.	1.6	0
383	Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, 1015-1022.	1.3	3
384	A Method for Evaluating Robustness of Limited Sampling Strategies Exemplified by Serum Iohexol Clearance for Determination of Measured Glomerular Filtration Rate. <i>Pharmaceutics</i> , 2023, 15, 1073.	2.0	1
385	Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
386	Neither Gastric Bypass Surgery Nor Diet-Induced Weight-Loss Affect OATP1B1 Activity as Measured by Rosuvastatin Oral Clearance. <i>Clinical Pharmacokinetics</i> , 2023, 62, 725-735.	1.6	1